ArticleGlobal & regional health technology assessment
Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases.
Cristian Lolli et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.